ArQule Message Board - Msg: 10611355

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule

ARQL 20.00

0.0%

Jan 16 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Herc who wrote (350)	7/22/1999 10:27:00 AM
From: tommysdad	Read Replies (1) of 399

<<ARQL and SEPR both design molecules for the drug industry. What other companies fulfill that niche?>> NOT true. SEPR takes KNOWN drugs and either (a) develops a KNOWN active metabolite or (b) separates the enantiomers and develops the eutomer (if you don't know what those terms mean, you may as well compare SEPR to ZZZBest). ARQL makes libraries of new molecules for other companies to test. <<What other companies fulfill that niche?>> Oh, PCOP, CCHM, Trega among public companies; at least half a dozen private companies.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next